A Phase III, multi-center, randomized, double-blind, 48 week study to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease
| Title | A Phase III, multi-center, randomized, double-blind, 48 week study to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease |
|---|---|
| Description | A Phase III, multi-center, randomized, double-blind, 48 week study with an initial 12 week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing's disease. The study aimed to demonstrate the superiority of osilodrostat compared to placebo in achieving a complete response at Week 12, to evaluate the safety of osilodrostat compared to placebo, and to evaluate the long-term safety and efficacy of osilodrostat. |
| Organism | Homo sapiens |
| Data Type | Other Type of Metabolome Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA015654 |
| Release Date | 2023-04-13 |
| Submitter | Xiao Hui Guo (bdyyguoxiaohui@sina.com) |
| Organization | Peking University First Hospital |
| Submission Date | 2023-03-22 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX003425-02 | pk data of 12 Chinese patients of LCI699C2302 | 12 | Other Type of Metabolome Data | 84.9 KB | xlsx | 0 | Controlled |